Pan Immune Inflammation Value for Perioperative Complications of Laparoscopic Sleeve Gastrectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

159 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Morbid obesity emerges as a problem that causes serious complications and increased mortality rates. The most effective treatment for morbid obesity today is surgical treatment. The most preferred type of surgery in morbid obesity surgery in Turkey and around the world is Laparoscopic Sleeve Gastrectomy (LSG).

While postoperative complications are divided into early and late complications, complications that develop during surgery and in the postoperative period before discharge are defined as perioperative complications. Early surgical complications after LSG include complications such as staple line bleeding, leaks, pulmonary thromboembolism, and torsion of the remnant stomach. It is important to detect these complications, which can be controlled with early intervention in the perioperative period.

Monitoring blood parameters and monitoring inflammation are methods that are easily accessible and provide rapid evaluation. Platelet lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), which are used in the evaluation and detection of postoperative complications, have shed light on studies in this direction. Pan immune inflammation value (PIV) is calculated from blood parameters and has been used to evaluate prognosis and chemotherapy results in colorectal cancer.

In this study, the diagnostic importance of changes in NLR, PLR, and PIV values in the preoperative and postoperative periods will be investigated in detecting complications that develop in the perioperative period before discharge in patients who underwent LSG.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Body Mass Index and Obesity Surgery Mortality Risk Score in Perioperative Complications of Laparoscopic Sleeve Gastrectomy

NCT04427644

Perioperative Complication Laparascopic Sleeve Gastrectomy BMD +3 more

COMPLETED

Weight Loss and Aggression

NCT05654584

Obesity Obesity, Morbid Aggression

UNKNOWN

Istmin Levels in Laparoscopik Sleeve Gastrectomy

NCT07335549

Obesity & Overweight Sleeve Gastrectomy Adipokines

COMPLETED

Nutritional Status After Sleeve Gastrectomy in Morbid Obesity: 6-Month Study

NCT06368232

Bariatric Surgery Candidate Gastrostomy Obesity

COMPLETED

The Effect of Laparoscopic Sleeve Gastrectomy on Blood Phoenixin-14 Levels

NCT07004556

Obesity, Morbid Obesity and Overweight

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who will undergo LSG due to morbid obesity will be included in the study. Patients who are completely healthy, not morbidly obese, and have no additional disease will be taken as the control group. Reference range values will be obtained by taking a complete blood count from the control group once. From patients who will undergo LSG, routine pre-operative complete blood count values, and postoperative 24th-hour complete blood count values will be taken. PLR, NLR, and PIV will be calculated manually from these complete blood count samples and the change in these parameters will be evaluated between patients who develop complications and those who do not.

In descriptive statistics, categorical data will be given as number (n) and percentage (%). Numerical data will be given as mean ± standard deviation (SD) (minimum-maximum data) or median (25% - 75% values) depending on their compliance with normal distribution. The Kolmogorov-Simirnov test will be used to determine the distribution of normality. A p-value \<0.05 is accepted as statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Morbid Obesity Laparoscopic Sleeve Gastrectomy Post Operative Complicaiton

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients without complications after LSG

Laparoscopic Sleeve Gastrectomy

Intervention Type PROCEDURE

Laparoscopic Sleeve Gastrectomy

Patients with complications after LSG

Laparoscopic Sleeve Gastrectomy

Intervention Type PROCEDURE

Laparoscopic Sleeve Gastrectomy

Control Group

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laparoscopic Sleeve Gastrectomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completely normal, healthy individuals with no additional diseases and BMI values of 19-24 kg/m2 for the control group
* Older than 18 years who will undergo Laparoscopic Sleeve Gastrectomy
* Patients with a body mass index (BMI) value ≥ 40 kg/m2 and no known comorbidities
* Patients with a BMI value ≥ 35 kg/m2 and additional comorbid diseases (such as Diabetes, Hypertension, Asthma, and Chronic Obstructive Pulmonary Disease)

Exclusion Criteria

* Individuals under 18 years of age and morbid obesity patients
* Patients who indicate elective surgery due to morbid obesity and who are planning for non-LSG morbid obesity surgery
* Patients who do not want to participate in the study
* Patients with additional diseases such as concurrent malignancy or rheumatological disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes